Clinical Trial Update: The Utility of Functionally Relevant Signature Genes in Assessing the Clinical Outcomes of Dupilumab Treatment [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating functionally relevant signature genes to assess outcomes of dupilumab in atopic dermatitis/eczema.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Dupilumab (dupilumab)

Snippet

Sponsor: Jonathan A. Bernstein, MD | Conditions: Atopic Dermatitis, Eczema | Phase 4 | Status: COMPLETED